Top

Current Treatment Options in Oncology

Published in:

01-08-2004

The emerging role of bortezomib in the treatment of indolent non-hodgkin’ and mantle cell lymphomas

Author: Owen A. O’Connor, MD, PhD

Published in: Current Treatment Options in Oncology | Issue 4/2004

Title: The emerging role of bortezomib in the treatment of indolent non-hodgkin’ and mantle cell lymphomas
Author: Owen A. O’Connor, MD, PhD
Publication date: 01-08-2004
Publisher: Current Medicine Group
Published in: Current Treatment Options in Oncology / Issue 4/2004
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-004-0018-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Please log in to get access to this content

Other articles of this Issue 4/2004

Multiple endocrine neoplasia type 2

Unusual functioning endocrine tumors

Treatment of T-cell non-hodgkin’ lymphoma

Persistent and recurrent hyperparathyroidism

Epratuzumab in non-hodgkin’ lymphomas

Bcl-2 antisense therapy in B-cell malignant proliferative disorders

Keynote webinar | Spotlight on antibody–drug conjugates in cancer